Drug intelligence / Profile preview

SLC-600

Development stage: Unknown
Lead developer: SignalChem Lifesciences
Modality: Small Molecules

Overview

SLC-600 is a small molecule drug candidate developed by SignalChem Lifesciences. It acts as an antagonist of the colony stimulating factor 1 receptor (CSF-1R), a protein kinase closely related to the growth and differentiation of human immune cells. By inhibiting CSF-1R, SLC-600 is designed to regulate and potentially improve immune responses in the context of cancer therapy. Its primary indication under investigation is for solid tumors[1][2][4].

Targets

CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on SLC-600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC-600.

Explore the full profile